Cellectis S.A.

CLLS | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.51

-$0.02 (-1.31%)

At close: Sep 21, 2026, 4:00 PM ET

$1.62

+$0.11 (+7.28%)

Pre-market: Sep 22, 2026, 6:11 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.31%

(1D)

Rating

Updated: Aug 31, 2026

47.5

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $151.63M

1D Range

1.46 1.54

52W Range

1.25 5.48

Valuation (TTM)

PE -2.29

PB 3.69

EV/EBITDA -1.39

Valuation (NTM)

Forward PE N/A

Forward PEG 0.14

Price Target $2.15

Cash Flow

FCF Yield -29.1%

SBC Adj. FCF Yield -30.6%

SBC Impact -5.2%

Margins

Gross Margin 74.7%

Operating Margin -105.9%

FCF Margin -77.9%

Growth (CAGR)

Revenue 3Y | 5Y 51.1% | -0.1%

Dil EPS 3Y | 5Y 30.1% | 39.6%

FCF 3Y | 5Y -452.4% | 42.0%

Returns

ROA -24.4%

ROE -94.1%

ROIC -41.0%

Financial Health

Net Cash

$112.87M

Current Ratio 1.37

Interest Coverage -7.27

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express ...

Sector Healthcare

Industry Biotechnology

Employees 229

IPO Date Mar 23, 2015

Website www.cellectis.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 13, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$2.15

Upside

+42.38%

Buy (1)

Hold (1)

Sell (1)

Analyst Details ➞